CXCR4 and neoplasm: Nearly 50% CXCR4 downregulation, inhibition of tumor proliferation, migration, invasion the malignancy, reversion of epithelial‐mesenchymal transition (EMT), increased chemosensitivity to the antitumor drug cisplatin